
Paul Blanche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7858633/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A closed maxâ€t test for multiple comparisons of areas under the ROC curve. Biometrics, 2022, 78, 352-363.	0.8	4
2	Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation. European Heart Journal, 2022, 43, e38-e44.	1.0	22
3	Temporal changes in myocardial infarction diagnostic criteria do not account for the lack of long-term beta-blocker effect on cardiovascular prognosis. European Heart Journal, 2022, 43, 836-838.	1.0	2
4	Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants. Heart, 2022, 108, 626-632.	1.2	10
5	Acute kidney injury and risk of cardiovascular outcomes: A nationwide cohort study. Nefrologia, 2022, 42, 338-346.	0.2	2
6	Electrical cardioversion of atrial fibrillation and the risk of brady-arrhythmic events. American Heart Journal, 2022, 244, 42-49.	1.2	3
7	Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. American Journal of Medicine, 2022, 135, 595-602.e5.	0.6	8
8	A hazard ratio above one does not necessarily mean higher risk, when using a time-dependent cox model. Research Methods in Medicine & Health Sciences, 2022, 3, 42-48.	0.7	0
9	Derivation and validation of the Rapid Assessment of Dementia Risk (RADaR) for older adults. PLoS ONE, 2022, 17, e0265379.	1.1	5
10	Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease. Annals of Internal Medicine, 2022, 175, 774-782.	2.0	7
11	Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 486-495.	1.4	3
12	Increased risk of neonatal complications and infections in children of kidney-transplanted women: A nationwide controlled cohort study. American Journal of Transplantation, 2021, 21, 1171-1178.	2.6	6
13	Risk of major cardiovascular events according to educational level before and after the initial COVID-19 public lockdown: a nationwide study. Journal of Epidemiology and Community Health, 2021, 75, 829-835.	2.0	6
14	Effect of government interventions to contain the COVID-19 pandemic on incidence of pulmonary embolism - A Danish nationwide register-based cohort study. Thrombosis Research, 2021, 199, 97-100.	0.8	6
15	Temporal trends and sex differences in sudden cardiac death in the Copenhagen City Heart Study. Heart, 2021, 107, 1303-1309.	1.2	17
16	Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study. European Heart Journal, 2021, 42, 2899-2908.	1.0	7
17	Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. European Heart Journal, 2021, 42, 907-914.	1.0	37
18	Confidence intervals for the cumulative incidence function via constrained NPMLE. Lifetime Data Analysis, 2020, 26, 45-64.	0.4	2

PAUL BLANCHE

#	Article	IF	CITATIONS
19	On evaluating how well a biomarker can predict treatment response with survival data. Pharmaceutical Statistics, 2020, 19, 410-423.	0.7	0
20	Thromboembolic events related to atrial fibrillation during the COVID-19 epidemic in Denmark. Thrombosis Research, 2020, 194, 220-221.	0.8	2
21	Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, 373-379.	1.4	5
22	Risk factors and a 3-month risk score for predicting pacemaker implantation in patients with atrial fibrillation. Open Heart, 2020, 7, e001125.	0.9	2
23	Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006260.	0.9	28
24	Effect of the antipsychotic drug haloperidol on arrhythmias during acute myocardial infarction in a porcine model. IJC Heart and Vasculature, 2020, 26, 100455.	0.6	2
25	Potassium Disturbances and Risk of Ventricular Fibrillation Among Patients With STâ€5egment–Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014160.	1.6	13
26	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and endâ€stage renal disease. European Journal of Heart Failure, 2020, 22, 813-820.	2.9	6
27	A covariateâ€specific timeâ€dependent receiver operating characteristic curve for correlated survival data. Statistics in Medicine, 2020, 39, 2477-2489.	0.8	1
28	Out-of-hospital cardiac arrest in patients with psychiatric disorders — Characteristics and outcomes. Resuscitation, 2019, 143, 180-188.	1.3	13
29	Decline in incidence of sudden cardiac death in the young: a 10-year nationwide study of 8756 deaths in Denmark. Europace, 2019, 21, 909-917.	0.7	9
30	Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. Nephrology Dialysis Transplantation, 2019, 34, 1961-1969.	0.4	13
31	Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. European Heart Journal, 2019, 40, 3782-3790.	1.0	29
32	Visit-to-Visit Variability of Hemoglobin A1c in People Without Diabetes and Risk of Major Adverse Cardiovascular Events and All-Cause Mortality. Diabetes Care, 2019, 42, 134-141.	4.3	36
33	The Wally plot approach to assess the calibration of clinical prediction models. Lifetime Data Analysis, 2019, 25, 150-167.	0.4	1
34	The c-index is not proper for the evaluation of \$t\$-year predicted risks. Biostatistics, 2019, 20, 347-357.	0.9	88
35	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 560-567.	3.0	206
36	An R ² â€eurve for evaluating the accuracy of dynamic predictions. Statistics in Medicine, 2018, 37, 1125-1133.	0.8	8

PAUL BLANCHE

#	Article	IF	CITATIONS
37	The risk of healing complications in primary teeth with concussion or subluxation injury—A retrospective cohort study. Dental Traumatology, 2017, 33, 337-344.	0.8	20
38	The risk of healing complications in primary teeth with extrusive or lateral luxation—A retrospective cohort study. Dental Traumatology, 2017, 33, 307-316.	0.8	16
39	The risk of healing complications in primary teeth with intrusive luxation: A retrospective cohort study. Dental Traumatology, 2017, 33, 329-336.	0.8	29
40	Receiver operating characteristic curve estimation for time to event with semicompeting risks and interval censoring. Statistical Methods in Medical Research, 2016, 25, 2750-2766.	0.7	6
41	A joint model for longitudinal and time-to-event data to better assess the specific role of donor and recipient factors on long-term kidney transplantation outcomes. European Journal of Epidemiology, 2016, 31, 469-479.	2.5	16
42	Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. European Journal of Heart Failure, 2015, 17, 828-836.	2.9	34
43	Quantifying and Comparing Dynamic Predictive Accuracy of Joint Models for Longitudinal Marker and Time-to-Event in Presence of Censoring and Competing Risks. Biometrics, 2015, 71, 102-113.	0.8	92
44	Prognostic Score for Predicting Risk of Dementia Over 10 Years While Accounting for Competing Risk of Death. American Journal of Epidemiology, 2014, 180, 790-798.	1.6	19
45	Concordance for prognostic models with competing risks. Biostatistics, 2014, 15, 526-539.	0.9	144
46	Review and comparison of ROC curve estimators for a timeâ€dependent outcome with markerâ€dependent censoring. Biometrical Journal, 2013, 55, 687-704.	0.6	58
47	Estimating and comparing timeâ€dependent areas under receiver operating characteristic curves for censored event times with competing risks. Statistics in Medicine, 2013, 32, 5381-5397.	0.8	1,010